Weight loss drugs are popular—but often expensive. Luckily, there are a few ways to lower the costs, which we explore in this article.

While Zepbound alone showed significant efficacy, patients combining it with PAP therapy ... your policies. Lilly Investors encourages patients to consult with their health care providers and ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

The Food and Drug Administration (FDA) on Dec. 20 approved the obesity medication Zepbound (tirzepatide) as the first pharmaceutical treatment for moderate-to-severe obstructive sleep apnea (OSA) in ...

You could pay about $171 per month for Mounjaro if you use a discount from the drug maker, Lilly, on top of insurance benefits ... can't get free Mounjaro through the drug maker's patient assistance ...

But for these dermatologic toxicities, patients often have to do these various things for skin care multiple times ... whether or not a patient assistance program is going to have enough funding ...

Cervical cancer screening is one of the best success stories in health care. Since the 1970s, the death rate from cervical ...

UAE -- The U.S. Food and Drug Administration (FDA) approved lately Tirzepatide, produced by Eli Lilly, as the first and only prescription ... with and without positive airway pressure (PAP) therapy ...

While this is all great news for Verzenio, Lilly isn't stopping its ambitions in oncology care with just one treatment. Right now, the company has seven clinical trials underway exploring new ...

Health-care companies slid after a profit warning from Eli Lilly. Shares of the obesity-drug maker tumbled after it slashed its projection for fourth-quarter revenue as the market for drugs that ...

Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on fierce rival Novo Nordisk’s early lead in the obesity market.